Literature DB >> 9491998

Massive expansion of antigen-specific CD8+ T cells during an acute virus infection.

E A Butz1, M J Bevan.   

Abstract

During LCMV infection, CD8+ T cells expand greatly. Bystander activation has been thought to play a role because few cells score as LCMV specific in limiting dilution analysis. In contrast, we find that at least a quarter of the CD8+ cells secrete IFNgamma specifically in response to LCMV peptides at the peak of the response. Moreover, by analyzing the expansion of adoptively transferred LCMV-specific, TCR-transgenic CD8+ T cells in congenic hosts, we have determined that most of the CD8+ cell expansion is virus specific. Analysis of the effect of the monospecific TCR-transgenic T cells on the host response to three LCMV epitopes suggests that CTL precursors compete for sites on the APC in an epitope-specific fashion and that this competition determines the specificity of the response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491998      PMCID: PMC2776648          DOI: 10.1016/s1074-7613(00)80469-0

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  44 in total

1.  Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection.

Authors:  D E Speiser; D Kyburz; U Stübi; H Hengartner; R M Zinkernagel
Journal:  J Immunol       Date:  1992-08-01       Impact factor: 5.422

2.  Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo.

Authors:  H Pircher; D Moskophidis; U Rohrer; K Bürki; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1990-08-16       Impact factor: 49.962

3.  Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens.

Authors:  Y J Liu; J Zhang; P J Lane; E Y Chan; I C MacLennan
Journal:  Eur J Immunol       Date:  1991-12       Impact factor: 5.532

4.  Phenotypic and functional analysis of the cellular response in regional lymphoid tissue during an acute virus infection.

Authors:  F Lynch; P C Doherty; R Ceredig
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

5.  T-cell imbalances and NK activity in varicella-zoster virus infections.

Authors:  R Cauda; E F Prasthofer; A B Tilden; R J Whitley; C E Grossi
Journal:  Viral Immunol       Date:  1987       Impact factor: 2.257

Review 6.  Peptides naturally presented by MHC class I molecules.

Authors:  H G Rammensee; K Falk; O Rötzschke
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

7.  TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide.

Authors:  I Bacik; J H Cox; R Anderson; J W Yewdell; J R Bennink
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

8.  T cell receptor antagonist peptides induce positive selection.

Authors:  K A Hogquist; S C Jameson; W R Heath; J L Howard; M J Bevan; F R Carbone
Journal:  Cell       Date:  1994-01-14       Impact factor: 41.582

9.  CD11b (Mac-1): a marker for CD8+ cytotoxic T cell activation and memory in virus infection.

Authors:  H I McFarland; S R Nahill; J W Maciaszek; R M Welsh
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

10.  High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response.

Authors:  S R Nahill; R M Welsh
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  254 in total

Review 1.  Death and destruction of activated T lymphocytes.

Authors:  I N Crispe
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Effects of cocaine administration to influenza virus-immunized mice on cytokine profiles of individual splenic CD4+ and CD8+ T cells.

Authors:  P Di Francesco; R Falchetti; R Gaziano; G Lanzilli; I A Casalinuovo; G Ravagnan; E Garaci
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

3.  Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity.

Authors:  A M Doling; J D Ballard; H Shen; K M Krishna; R Ahmed; R J Collier; M N Starnbach
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

Review 4.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

Review 5.  T-cell proliferation in vivo and the role of cytokines.

Authors:  J Sprent; X Zhang; S Sun; D Tough
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

6.  Application of the intracellular gamma interferon assay to recalculate the potency of CD8(+) T-cell responses to herpes simplex virus.

Authors:  U Kumaraguru; B T Rouse
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 7.  Recent developments in flow cytometry.

Authors:  A Scheffold; F Kern
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

8.  Quantitative analysis of the acute and long-term CD4(+) T-cell response to a persistent gammaherpesvirus.

Authors:  J P Christensen; P C Doherty
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

9.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

10.  CD8(+) T-cell selection, function, and death in the primary immune response in vivo.

Authors:  M F Callan; C Fazou; H Yang; T Rostron; K Poon; C Hatton; A J McMichael
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.